TransIT® VirusGEN® SELECT Transfection Reagent and Kits
Mirus Bio Kontakt z doradcąTransfection Reagent and Kits For Large Scale Production of AAV and Lentivirus used in Preclinical and Early Phase Clinical Trials
TransIT-VirusGEN® SELECT Transfection Reagent is designed to enhance delivery of packaging and transfer vector DNA to suspension and adherent HEK 293 cell types in order to increase production of recombinant lentivirus and adeno-associated virus (AAV).
Key benefits of TransIT-VirusGEN® SELECT Transfection Reagent include:
- Performance – Efficient DNA delivery for large-scale production of high-titer viral vectors
- Quality – Tested for performance, appearance, identity, sterility, endotoxin and mycoplasma
- Flexibility – Compatible with different virus production platforms and repeat filtration
- Animal Origin Free – Fully synthetic transfection reagent formulation
With industry-leading performance in high-titer virus manufacturing, TransIT-VirusGEN® SELECT offers a simplified, cost-effective workflow, making it an excellent choice for large-scale virus production in preclinical studies and early-phase clinical trials. Titers can be further increased with optimized enhancers included in the VirusGEN® SELECT AAV Transfection Kit and VirusGEN® SELECT LV Transfection Kit. When transitioning to late-phase clinical trials or commercial manufacturing, we recommend TransIT-VirusGEN® GMP.